Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study
VE Georgakopoulou, D Basoulis… - Experimental and …, 2022 - spandidos-publications.com
The severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2) pandemic is a
significant global issue that has major implications for the healthcare system. The mortality …
significant global issue that has major implications for the healthcare system. The mortality …
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …
Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab
A Ramón, M Zaragozá, AM Torres, J Cascón… - Journal of Clinical …, 2022 - mdpi.com
Among the IL-6 inhibitors, tocilizumab is the most widely used therapeutic option in patients
with SARS-CoV-2-associated severe respiratory failure (SRF). The aim of our study was to …
with SARS-CoV-2-associated severe respiratory failure (SRF). The aim of our study was to …
Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review
X Zhang, Y You, P Zhang, Y Wang, F Shen - Future Science OA, 2024 - Taylor & Francis
Immune checkpoint inhibitors (ICIs) have gained widespread application in the treatment of
malignant tumors. Cytokine release syndrome (CRS) is a systemic inflammatory response …
malignant tumors. Cytokine release syndrome (CRS) is a systemic inflammatory response …
Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab
A Killer, S Gliga, P Massion, C Ackermann… - Infection, 2024 - Springer
Purpose The IL-6 receptor inhibitor tocilizumab reduces mortality and morbidity in severe
cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant …
cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant …
Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot …
Background: The optimal approach for adult patients hospitalized with severe and critical
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …
Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
Z Gáspár, BG Szabó, H Andrikovics, A Ceglédi… - GeroScience, 2024 - Springer
Baricitinib is considered a first-line treatment for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm …
coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm …
肿瘤免疫治疗所致细胞因子释放综合征的研究进展
刘燕， 贾煜娴， 李婷婷 - 中国癌症防治杂志, 2022 - zgazfz.com
近年来, 肿瘤免疫疗法取得了显著的临床疗效, 但部分患者会产生免疫介导毒性,
其中最常见的是细胞因子释放综合征(cytokine release syndrome, CRS). CRS …
其中最常见的是细胞因子释放综合征(cytokine release syndrome, CRS). CRS …
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study
L Masotti, G Landini, G Panigada, E Grifoni… - International …, 2022 - Elsevier
Abstract Introduction Despite Tocilizumab is now recognized as a concrete therapeutic
option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about …
option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about …
[HTML][HTML] Clinical predictors of response to tocilizumab: A retrospective multicenter study
S Ercan, B Ergan, SS Özuygur, P Korkmaz… - Turkish thoracic …, 2022 - ncbi.nlm.nih.gov
OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19)
demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical …
demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical …